Unknown

Dataset Information

0

Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants.


ABSTRACT:

Background

Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated.

Methods

We exome sequenced 240 cases with thoracic aortic dissection and 258 controls, then examined 11 aortopathy genes. Pathogenic variants in 6 aortopathy genes (COL3A1, FBN1, LOX, PRKG1, SMAD3, and TGFBR2) were identified in 26 participants, representing 10.8% of the cohort (26/240). A second research sample was used to validate the initial findings. Mailed letters to participants disclosed that a potentially disease causing DNA alteration had been identified (neither the gene nor variant was disclosed). Participants were offered clinical genetic counseling and confirmatory genetic testing in a CLIA laboratory.

Results

Excluding 6 participants who were deceased or lost to follow-up, 20 participants received the disclosure letter, 10 of whom proceeded with genetic counseling, confirmatory genetic testing, and enrolled in a survey study. Participants reported satisfaction with the letter (4.2?±?0.7) and genetic counseling (4.4?±?0.4; [out of 5, respectively]). The psychosocial impact was characterized by low decisional regret (11.5?±?11.6) and distress (16.0?±?4.2, [out of 100, respectively]). The average cost for 26 participants was $400, including validation and sending letters. The average cost for those who received genetic counseling and CLIA laboratory confirmation was $605.

Conclusions

Participants were satisfied with the return of clinically significant biobank genetic results and CLIA laboratory testing; however, the process required significant time and resources. These findings illustrate the trade-offs involved for researchers considering returning research genetic results.

SUBMITTER: Beil A 

PROVIDER: S-EPMC7923508 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants.

Beil Adelyn A   Hornsby Whitney W   Uhlmann Wendy R WR   Aatre Rajani R   Arscott Patricia P   Wolford Brooke B   Eagle Kim A KA   Yang Bo B   McNamara Jennifer J   Willer Cristen C   Roberts J Scott JS  

BMC medical genomics 20210301 1


<h4>Background</h4>Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated.<h4>Methods</h4>We exome sequenced 240 cases with thoracic aortic dissection and 258 controls, then examined 11 aortopathy genes. Pathogenic variants in 6 aortopathy genes (COL3A1, FBN1, LOX, PRKG1, SMAD3, and TGFBR2) were ide  ...[more]

Similar Datasets

| S-EPMC3990573 | biostudies-literature
| S-EPMC7438314 | biostudies-literature
| S-EPMC6582991 | biostudies-literature
| S-EPMC5125072 | biostudies-literature
| S-EPMC5031368 | biostudies-literature
| S-EPMC7033893 | biostudies-literature
| S-EPMC8774627 | biostudies-literature